Institute of Biomedical & Clinical Science: Recent submissions
Now showing items 11-15 of 1232
-
Meeting the Challenge of Virtual Diabetes Care: A Consensus Viewpoint on the Positioning and Value of Oral Semaglutide in Routine Clinical Practice
(Springer, 19 January 2022)While glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as semaglutide, are among the most effective drugs for treating people with type 2 diabetes (T2D), they are clinically under-utilised. Until recently, the ... -
Defining the role of SGLT2 inhibitors in primary care: Time to think differently.
(Springer, 29 March 2022)Disease burden in people with diabetes is mainly driven by long-term complications such as cardiovascular disease, heart failure and chronic kidney disease. This is a consequence of the interconnection between the ... -
The impact of COVID vaccination on symptoms of long COVID: An international survey of people with lived experience of long COVID.
(MDPI, 21 April 2022)Long COVID is a multi-system syndrome following SARS-CoV-2 infection with persistent symptoms of at least 4 weeks, and frequently for several months. It has been suggested that there may be an autoimmune component. There ... -
The role of sodium-glucose co-transporter-2 inhibitors in frail older adults with or without type 2 diabetes mellitus
(Oxford University Press / British Geriatrics Society, 6 October 2022)Sodium-glucose co-transporter-2 (SGLT2) inhibitors offer significant outcome benefits beyond glucose lowering including reduced risk of cardiovascular death, all-cause mortality, major adverse cardiovascular events, ... -
Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial.
(Elsevier, 22 May 2019)BACKGROUND: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype ...